Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...

Resmed CEO Mick Farrell addressed the latest potential threats to the CPAP therapy market during a recent webcast: The ...

ASX heath sector fell 0.65% in past five days. Morgans' Scott Power notes the June quarterly reporting season has been 'mostly pretty good'.

Topline results were announced from a second phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in patients with OSA.